Since different molecular mechanisms between AR and FOXA1 signaling pathways have been suggested in ER-negative breast cancers, the clinical implications of AR and FOXA1 status on patient prognosis should be further investigated to improve the survival of patients with heterogeneous breast cancers. This evidence concerns the gene FOXA1 and breast cancer.